Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC network study.

Labreche K, Daniau M, Sud A, Law PJ, Royer-Perron L, Holroyd A, Broderick P, Went M, Benazra M, Ahle G, Soubeyran P, Taillandier L, Chinot OL, Casasnovas O, Bay JO, Jardin F, Oberic L, Fabbro M, Damaj G, Brion A, Mokhtari K, Philippe C, Sanson M, Houillier C, Soussain C, Hoang-Xuan K, Houlston RS, Alentorn A; LOC Network.

Neuro Oncol. 2019 May 17. pii: noz088. doi: 10.1093/neuonc/noz088. [Epub ahead of print]

PMID:
31102405
2.

[Clinical trials and elderly patients with cancer, the Geriatric Core Dataset (G-Code) tool].

Paillaud E, Cudennec T, Caillet P, Bellera C, Mathoulin-Pélissier S, Soubeyran P.

Soins Gerontol. 2019 May - Jun;24(137):35-37. doi: 10.1016/j.sger.2019.03.010. Review. French.

PMID:
31084807
3.

A systematic review on the association of the G8 with geriatric assessment, prognosis and course of treatment in older patients with cancer.

van Walree IC, Scheepers E, van Huis-Tanja LH, Emmelot-Vonk MH, Bellera C, Soubeyran P, Hamaker ME.

J Geriatr Oncol. 2019 May 8. pii: S1879-4068(19)30099-2. doi: 10.1016/j.jgo.2019.04.016. [Epub ahead of print] Review.

PMID:
31078444
4.

Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis.

Santofimia-Castaño P, Xia Y, Lan W, Zhou Z, Huang C, Peng L, Soubeyran P, Velázquez-Campoy A, Abián O, Rizzuti B, Neira JL, Iovanna J.

J Clin Invest. 2019 Mar 28;129(6):2500-2513. doi: 10.1172/JCI127223.

5.

Determinants of functional decline in older adults experiencing cancer (the INCAPAC study).

Galvin A, Helmer C, Coureau G, Amadeo B, Rainfray M, Soubeyran P, Dartigues JF, Pérès K, Bellera C, Delva F, Mathoulin-Pélissier S.

J Geriatr Oncol. 2019 Mar 20. pii: S1879-4068(18)30400-4. doi: 10.1016/j.jgo.2019.03.006. [Epub ahead of print]

PMID:
30902591
6.

Role of Calcium Signaling in GA101-Induced Cell Death in Malignant Human B Cells.

Latour S, Zanese M, Le Morvan V, Vacher AM, Menard N, Bijou F, Durrieu F, Soubeyran P, Savina A, Vacher P, Bresson-Bepoldin L.

Cancers (Basel). 2019 Mar 1;11(3). pii: E291. doi: 10.3390/cancers11030291.

7.

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.

Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Moluçon-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C; Intergroupe GOELAMS–ANOCEF and the LOC Network for CNS Lymphoma.

J Clin Oncol. 2019 Apr 1;37(10):823-833. doi: 10.1200/JCO.18.00306. Epub 2019 Feb 20.

PMID:
30785830
8.

Modulation of the ATM/autophagy pathway by a G-quadruplex ligand tips the balance between senescence and apoptosis in cancer cells.

Beauvarlet J, Bensadoun P, Darbo E, Labrunie G, Rousseau B, Richard E, Draskovic I, Londono-Vallejo A, Dupuy JW, Nath Das R, Guédin A, Robert G, Orange F, Croce S, Valesco V, Soubeyran P, Ryan KM, Mergny JL, Djavaheri-Mergny M.

Nucleic Acids Res. 2019 Apr 8;47(6):2739-2756. doi: 10.1093/nar/gkz095.

9.

The prognostic value of G8 for functional decline.

Chakiba C, Bellera C, Etchepare F, Mathoulin-Pelissier S, Rainfray M, Soubeyran P.

J Geriatr Oncol. 2019 Jan 9. pii: S1879-4068(18)30265-0. doi: 10.1016/j.jgo.2018.12.004. [Epub ahead of print]

PMID:
30638869
10.

Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype.

Swayden M, Iovanna J, Soubeyran P.

Heliyon. 2018 Dec 17;4(12):e01055. doi: 10.1016/j.heliyon.2018.e01055. eCollection 2018 Dec. Review.

11.

Ribonuclease MCPiP1 contributes to the loss of micro-RNA-200 family members in pancreatic cancer cells.

Boudouresque F, Siret C, Dobric A, Silvy F, Soubeyran P, Iovanna J, Lombardo D, Berthois Y.

Oncotarget. 2018 Nov 13;9(89):35941-35961. doi: 10.18632/oncotarget.26310. eCollection 2018 Nov 13.

12.

Inactivation of NUPR1 promotes cell death by coupling ER-stress responses with necrosis.

Santofimia-Castaño P, Lan W, Bintz J, Gayet O, Carrier A, Lomberk G, Neira JL, González A, Urrutia R, Soubeyran P, Iovanna J.

Sci Rep. 2018 Nov 19;8(1):16999. doi: 10.1038/s41598-018-35020-3.

13.

Calcium Independent Effect of Orai1 and STIM1 in Non-Hodgkin B Cell Lymphoma Dissemination.

Latour S, Mahouche I, Cherrier F, Azzi-Martin L, Velasco V, Soubeyran P, Merlio JP, Poglio S, Bresson-Bepoldin L.

Cancers (Basel). 2018 Oct 26;10(11). pii: E402. doi: 10.3390/cancers10110402.

14.

Multidisciplinary development of the Geriatric Core Dataset for clinical research in older patients with cancer: A French initiative with international survey.

Paillaud E, Soubeyran P, Caillet P, Cudennec T, Brain E, Terret C, Etchepare F, Mourey L, Aparicio T, Pamoukdjian F, Audisio RA, Rostoft S, Hurria A, Bellera C, Mathoulin-Pélissier S; G-CODE collaborators.

Eur J Cancer. 2018 Nov;103:61-68. doi: 10.1016/j.ejca.2018.07.137. Epub 2018 Sep 11.

PMID:
30212804
15.

Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.

Gyan E, Sonet A, Brice P, Anglaret B, Laribi K, Fruchart C, Tilly H, Araujo C, Soubeyran P, Gonzalez H, Morineau N, Nicolas-Virelizier E, Ghesquières H, Salles B, Bouabdallah R, Orfeuvre H, Fahri J, Couturier O, Xerri L, Feugier P; Lymphoma Study Association (LYSA).

Br J Haematol. 2018 Oct;183(1):76-86. doi: 10.1111/bjh.15513. Epub 2018 Aug 16.

PMID:
30117149
16.

Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma.

Molejon MI, Swayden M, Fanale D, Bintz J, Gayet O, Soubeyran P, Iovanna J.

Oncotarget. 2018 Jul 20;9(56):30837-30846. doi: 10.18632/oncotarget.25745. eCollection 2018 Jul 20.

17.

mTOR Inhibition via Displacement of Phosphatidic Acid Induces Enhanced Cytotoxicity Specifically in Cancer Cells.

Nguyen TL, Nokin MJ, Egorov M, Tomé M, Bodineau C, Di Primo C, Minder L, Wdzieczak-Bakala J, Garcia-Alvarez MC, Bignon J, Thoison O, Delpech B, Surpateanu G, Frapart YM, Peyrot F, Abbas K, Terés S, Evrard S, Khatib AM, Soubeyran P, Iorga BI, Durán RV, Collin P.

Cancer Res. 2018 Sep 15;78(18):5384-5397. doi: 10.1158/0008-5472.CAN-18-0232. Epub 2018 Jul 27.

PMID:
30054335
18.

Determinants of cancer treatment and mortality in older cancer patients using a multi-state model: Results from a population-based study (the INCAPAC study).

Galvin A, Helmer C, Coureau G, Amadeo B, Joly P, Sabathé C, Monnereau A, Baldi I, Rainfray M, Soubeyran P, Delva F, Mathoulin-Pélissier S.

Cancer Epidemiol. 2018 Aug;55:39-44. doi: 10.1016/j.canep.2018.04.013. Epub 2018 May 25.

PMID:
29763754
19.

Alterations in comprehensive geriatric assessment decrease survival of elderly patients with cancer.

Frasca M, Soubeyran P, Bellera C, Rainfray M, Leffondre K, Mathoulin-Pélissier S; oncodage group.

Eur J Cancer. 2018 Feb;90:10-18. doi: 10.1016/j.ejca.2017.11.013. Epub 2017 Dec 18.

PMID:
29268140
20.

Impact of geriatric assessment for the therapeutic decision-making of breast cancer: results of a French survey. AFSOS and SOFOG collaborative work.

Falandry C, Krakowski I, Curé H, Carola E, Soubeyran P, Guérin O, Gaudin H, Freyer G.

Breast Cancer Res Treat. 2018 Apr;168(2):433-441. doi: 10.1007/s10549-017-4607-8. Epub 2017 Dec 14.

PMID:
29243107
21.

ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma.

Buske C, Hutchings M, Ladetto M, Goede V, Mey U, Soubeyran P, Spina M, Stauder R, Trnený M, Wedding U, Fields P; ESMO Lymphoma Consensus Conference Panel Members.

Ann Oncol. 2018 Mar 1;29(3):544-562. doi: 10.1093/annonc/mdx413.

PMID:
29194473
22.

R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.

Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K, Benchalal M, Moles MP, Le Gouill S, Fleury J, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Tournilhac O, Branger B, Devillers A, Vuillez JP, Fest T, Colombat P, Costes V, Szablewski V, Béné MC, Delwail V; LYSA Group.

Blood. 2018 Jan 11;131(2):174-181. doi: 10.1182/blood-2017-07-793984. Epub 2017 Oct 23.

23.

Sociodemographic, socioeconomic, and clinical determinants of survival in patients with cancer: A systematic review of the literature focused on the elderly.

Galvin A, Delva F, Helmer C, Rainfray M, Bellera C, Rondeau V, Soubeyran P, Coureau G, Mathoulin-Pélissier S.

J Geriatr Oncol. 2018 Jan;9(1):6-14. doi: 10.1016/j.jgo.2017.07.007. Epub 2017 Oct 10.

PMID:
29030150
24.

Rational therapeutic choice for older patients with lymphoma.

Bron D, Soubeyran P; EHA SWG on ‘Aging, Hematology’.

Curr Opin Oncol. 2017 Sep;29(5):322-327. doi: 10.1097/CCO.0000000000000394. Review.

PMID:
28742622
25.

Intrinsically disordered chromatin protein NUPR1 binds to the C-terminal region of Polycomb RING1B.

Santofimia-Castaño P, Rizzuti B, Pey ÁL, Soubeyran P, Vidal M, Urrutia R, Iovanna JL, Neira JL.

Proc Natl Acad Sci U S A. 2017 Jul 18. pii: 201619932. doi: 10.1073/pnas.1619932114. [Epub ahead of print]

26.

Immune checkpoint inhibitors and elderly people: A review.

Daste A, Domblides C, Gross-Goupil M, Chakiba C, Quivy A, Cochin V, de Mones E, Larmonier N, Soubeyran P, Ravaud A.

Eur J Cancer. 2017 Sep;82:155-166. doi: 10.1016/j.ejca.2017.05.044. Epub 2017 Jul 6. Review.

PMID:
28689093
27.

Unmet needs in the scientific approach to older patients with lymphoma.

Bron D, Aurer I, André MPE, Bonnet C, Caballero D, Falandry C, Kimby E, Soubeyran P, Zucca E, Bosly A, Coiffier B; European Lymphoma Institute (ELI) Group and the EHA SWG “Aging and Hematology”.

Haematologica. 2017 Jun;102(6):972-975. doi: 10.3324/haematol.2017.167619. Review. No abstract available.

28.

Modeling individual and relative accuracy of screening tools in geriatric oncology.

Bellera CA, Artaud F, Rainfray M, Soubeyran PL, Mathoulin-Pélissier S.

Ann Oncol. 2017 May 1;28(5):1152-1157. doi: 10.1093/annonc/mdx068.

29.

mTORC1 inhibition in cancer cells protects from glutaminolysis-mediated apoptosis during nutrient limitation.

Villar VH, Nguyen TL, Delcroix V, Terés S, Bouchecareilh M, Salin B, Bodineau C, Vacher P, Priault M, Soubeyran P, Durán RV.

Nat Commun. 2017 Jan 23;8:14124. doi: 10.1038/ncomms14124.

30.

Regulation of NUB1 Activity through Non-Proteolytic Mdm2-Mediated Ubiquitination.

Bonacci T, Audebert S, Camoin L, Baudelet E, Iovanna JL, Soubeyran P.

PLoS One. 2017 Jan 18;12(1):e0169988. doi: 10.1371/journal.pone.0169988. eCollection 2017.

31.

Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.

Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquières H, Houot R, Larrieu D, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Choquet S, Alentorn A, Leclercq D, Omuro A, Tanguy ML, Hoang-Xuan K.

Neuro Oncol. 2017 Mar 1;19(3):422-429. doi: 10.1093/neuonc/now238.

32.

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.

Kraeber-Bodere F, Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Jardel H, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Gouilleux-Gruart V, Barbet J, Wegener WA, Goldenberg DM, Lamy T, Soubeyran P.

Lancet Haematol. 2017 Jan;4(1):e35-e45. doi: 10.1016/S2352-3026(16)30168-5. Epub 2016 Dec 8.

PMID:
27964867
33.

Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.

Ruella M, Soubeyran P.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):432-436. Review.

34.

Treatment of the elderly patient with mantle cell lymphoma.

Soubeyran P, Gressin R.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):425-431. Review.

35.

Role of geriatric intervention in the treatment of older patients with cancer: rationale and design of a phase III multicenter trial.

Soubeyran P, Terret C, Bellera C, Bonnetain F, Jean OS, Galvin A, Chakiba C, Zwolakowski MD, Mathoulin-Pélissier S, Rainfray M.

BMC Cancer. 2016 Dec 1;16(1):932.

36.

Targeted therapy and elderly people: A review.

Daste A, Chakiba C, Domblides C, Gross-Goupil M, Quivy A, Ravaud A, Soubeyran P.

Eur J Cancer. 2016 Dec;69:199-215. doi: 10.1016/j.ejca.2016.10.005. Epub 2016 Nov 15. Review.

PMID:
27855351
37.

Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients.

Kurtz JE, Soubeyran P, Michallet M, Luporsi E, Albrand H.

Onco Targets Ther. 2016 Oct 28;9:6689-6693. eCollection 2016.

38.

Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.

Mesguich C, Cazeau AL, Bouabdallah K, Soubeyran P, Guyot M, Milpied N, Bordenave L, Hindié E.

Br J Haematol. 2016 Nov;175(4):652-660. doi: 10.1111/bjh.14292. Epub 2016 Aug 19.

PMID:
27539369
39.

Innovative approach to older patients with malignant hemopathies.

Bron D, Soubeyran P, Fulop T; SWG “Aging and Hematology” of the EHA.

Haematologica. 2016 Aug;101(8):893-5. doi: 10.3324/haematol.2016.142810. No abstract available.

40.

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.

Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, Brice P, Soubeyran P, Gomes Da Silva M, Mounier C, Offner F, Dupuis J, Caballero D, Canioni D, Paula M, Delarue R, Zachee P, Seymour J, Salles G, Tilly H.

J Clin Oncol. 2016 Aug 1;34(22):2575-82. doi: 10.1200/JCO.2015.65.7163. Epub 2016 Jun 13. Erratum in: J Clin Oncol. 2016 Sep 10;34(26):3230.

PMID:
27298402
41.

[Comprehensive geriatric assessment (CGA) in elderly with cancer: For whom?].

Liuu E, Caillet P, Curé H, Anfasi N, De Decker L, Pamoukdjian F, Canouï-Poitrine F, Soubeyran P, Paillaud E; sous l’égide de la Société francophone d’oncogériatrie (SoFOG).

Rev Med Interne. 2016 Jul;37(7):480-8. doi: 10.1016/j.revmed.2016.02.004. Epub 2016 Mar 17. French.

PMID:
26997159
42.

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.

Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, Soubeyran P, Lamy T, Morschhauser F, Benouaich-Amiel A, Ahle G, Moles-Moreau MP, Moluçon-Chabrot C, Bourquard P, Damaj G, Jardin F, Larrieu D, Gyan E, Gressin R, Jaccard A, Choquet S, Brion A, Casasnovas O, Colin P, Reman O, Tempescul A, Marolleau JP, Fabbro M, Naudet F, Hoang-Xuan K, Houot R.

Neuro Oncol. 2016 Sep;18(9):1297-303. doi: 10.1093/neuonc/now033. Epub 2016 Mar 6.

43.

Predictive factors of depressive symptoms of elderly patients with cancer receiving first-line chemotherapy.

Duc S, Rainfray M, Soubeyran P, Fonck M, Blanc JF, Ceccaldi J, Cany L, Brouste V, Mathoulin-Pélissier S.

Psychooncology. 2017 Jan;26(1):15-21. doi: 10.1002/pon.4090. Epub 2016 Feb 23.

PMID:
26913707
44.

Detection of frailty in elderly cancer patients: Improvement of the G8 screening test.

Petit-Monéger A, Rainfray M, Soubeyran P, Bellera CA, Mathoulin-Pélissier S.

J Geriatr Oncol. 2016 Mar;7(2):99-107. doi: 10.1016/j.jgo.2016.01.004. Epub 2016 Feb 8.

PMID:
26868830
45.

One-Year Mortality in Older Patients with Cancer: Development and External Validation of an MNA-Based Prognostic Score.

Bourdel-Marchasson I, Diallo A, Bellera C, Blanc-Bisson C, Durrieu J, Germain C, Mathoulin-Pélissier S, Soubeyran P, Rainfray M, Fonck M, Doussau A.

PLoS One. 2016 Feb 9;11(2):e0148523. doi: 10.1371/journal.pone.0148523. eCollection 2016.

46.

Optimizing the G8 Screening Tool for Older Patients With Cancer: Diagnostic Performance and Validation of a Six-Item Version.

Martinez-Tapia C, Canoui-Poitrine F, Bastuji-Garin S, Soubeyran P, Mathoulin-Pelissier S, Tournigand C, Paillaud E, Laurent M, Audureau E; ELCAPA Study Group.

Oncologist. 2016 Feb;21(2):188-95. doi: 10.1634/theoncologist.2015-0326. Epub 2016 Jan 13.

47.

Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.

Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Touitou V, Barrié M, del Rio MS, Gonzalez-Aguilar A, Houillier C, Delgadillo D, Lacomblez L, Tanguy ML, Hoang-Xuan K.

Lancet Haematol. 2015 Jun;2(6):e251-9. doi: 10.1016/S2352-3026(15)00074-5. Epub 2015 Jun 3.

PMID:
26688235
48.

[How to identify frailty in older patients with cancer? Available tools].

Bellera C, Soubeyran P.

Cancer Radiother. 2015 Oct;19(6-7):382-5. doi: 10.1016/j.canrad.2015.07.154. Epub 2015 Aug 25. French.

PMID:
26321648
49.

Localized Store-Operated Calcium Influx Represses CD95-Dependent Apoptotic Effects of Rituximab in Non-Hodgkin B Lymphomas.

Vacher P, Vacher AM, Pineau R, Latour S, Soubeyran I, Pangault C, Tarte K, Soubeyran P, Ducret T, Bresson-Bepoldin L.

J Immunol. 2015 Sep 1;195(5):2207-15. doi: 10.4049/jimmunol.1402942. Epub 2015 Jul 22.

50.

Editorial: manipulation of the cellular microbicidal response and endocytic dynamic by pathogens membrane factors.

Coiffard B, Soubeyran P, Ghigo E.

Front Cell Infect Microbiol. 2015 May 29;5:42. doi: 10.3389/fcimb.2015.00042. eCollection 2015. No abstract available.

Supplemental Content

Loading ...
Support Center